Strong vaccine responses during chemotherapy are associated with prolonged cancer survival

Baseline peripheral blood leukocytosis: Biological marker predicts outcome in oropharyngeal cancer, regardless of HPV-status

(2018) Zeno A.R. Gouw et al.   ORAL ONCOLOGY

The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival

(2018) S. J. A. M. Santegoets et al.   OncoImmunology

Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer

(2018) Erminia Massarelli et al.   JAMA Oncology

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

(2017) Krishnansu S Tewari et al.   LANCET

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor-related leukocytosis is associated with poor radiation response and clinical outcome in uterine cervical cancer patients

(2016) Y. Cho et al.   ANNALS OF ONCOLOGY

Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells

(2016) E. Beyranvand Nejad et al.   CANCER RESEARCH

Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response

(2016) M. I. E. van Poelgeest et al.   CLINICAL CANCER RESEARCH

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

(2016) Paul T. Nghiem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses

(2016) Marij J. Welters et al.   Science Translational Medicine

Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry

(2015) Saskia J. A. M. Santegoets et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505

(2015) Ryo Kitagawa et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

(2015) Cornelia L Trimble et al.   LANCET

Combination cancer immunotherapies tailored to the tumour microenvironment

(2015) Mark J. Smyth et al.   Nature Reviews Clinical Oncology

Vaccine-Induced Tumor Necrosis Factor-Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death

(2014) T. C. van der Sluis et al.   CLINICAL CANCER RESEARCH

A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer

(2014) Domenica Lorusso et al.   GYNECOLOGIC ONCOLOGY

Improved Survival with Bevacizumab in Advanced Cervical Cancer

(2014) Krishnansu S. Tewari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response

(2014) P. Kvistborg et al.   Science Translational Medicine

Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma

(2013) S. Lyford-Pike et al.   CANCER RESEARCH

HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial

(2013) Mariette I E van Poelgeest et al.   Journal of Translational Medicine

The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools

(2012) Satwinder Kaur Singh et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: A phase I/II clinical trial

(2012) Eliane C.M. Zeestraten et al.   INTERNATIONAL JOURNAL OF CANCER

Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses

(2012) M. L. Bagarazzi et al.   Science Translational Medicine

IFN-  enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing

(2011) F. Spadaro et al.   BLOOD

Direct Effects of Type I Interferons on Cells of the Immune System

(2011) S. Hervas-Stubbs et al.   CLINICAL CANCER RESEARCH

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses

(2010) M. J. P. Welters et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study

(2009) Bradley J. Monk et al.   JOURNAL OF CLINICAL ONCOLOGY

Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia

(2009) Gemma G. Kenter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Surgery followed by Persistence of High-Grade Squamous Intraepithelial Lesions Is Associated with the Induction of a Dysfunctional HPV16-Specific T-Cell Response

(2008) P. J. de Vos van Steenwijk et al.   CLINICAL CANCER RESEARCH

Human Leukocyte Antigen Class I, MHC Class I Chain-Related Molecule A, and CD8+/Regulatory T-Cell Ratio: Which Variable Determines Survival of Cervical Cancer Patients?

(2008) E. S. Jordanova et al.   CLINICAL CANCER RESEARCH

Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine

(2008) M. J.P. Welters et al.   CLINICAL CANCER RESEARCH

Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

(2008) G. G. Kenter et al.   CLINICAL CANCER RESEARCH